Pathfinders in Biopharma

46 Folgen

1. ECM: Robust End to Year, Despite Previous Volatility

   Vom: 31.10.2023
2. Biotech Halftime Report: A Winding Road Ahead

   Vom: 26.9.2023
3. The Urgent Need to Address the Youth Mental Health Landscape

   Vom: 17.8.2023
4. Website Traffic Reveals Biopharma Sales Trends

   Vom: 7.8.2023
5. When to Call it Quits: VCs Making Tough Decisions in a Tough Market

   Vom: 13.7.2023
6. How Biotech M&A is Redefining the Strategic Landscape

   Vom: 23.6.2023
7. Healthcare Should Get Ready for ‘Fast and Furious’ M&A

   Vom: 8.6.2023
8. Innovation and Growth: Key Ingredients to Healthcare M&A

   Vom: 7.6.2023
9. Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

   Vom: 2.6.2023
10. Global Blood Therapeutics Commitment to Sickle-Cell Innovation

    Vom: 22.5.2023
11. Is This the Breakthrough Moment for Genetic Medicine?

    Vom: 13.4.2023
12. The Hidden Revolution Set to Turn US Healthcare on its Head

    Vom: 26.1.2023
13. The Big Picture for Biotech

    Vom: 13.12.2022
14. Why Biopharma Investment Requires a Different Mindset

    Vom: 22.11.2022
15. The Optimism Behind the Biopharma Market

    Vom: 3.10.2022
16. Biotech Investors: How to Find Value in a Bear Market

    Vom: 21.3.2022
17. A call to action: Global Blood Therapeutics on tackling orphan disease

    Vom: 8.12.2021
18. Ionis: Raising The Bar For ESG

    Vom: 28.10.2021
19. Biotech and Big Pharma: Blueprint for Successful Partnership

    Vom: 30.9.2021
20. What’s Material in ESG for Biopharma Firms?

    Vom: 4.5.2021